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ribavirin (TPV + PegIFN/RBV) remains a therapeutic option for
chronic hepatitis C virus (HCV) genotype (GT) 1 infection in many
regions. We conducted two open-label, phase IIIb trials compar-
ing safety and efficacy of all-oral ombitasvir/paritaprevir/
ritonavir and dasabuvir ± ribavirin (OBV/PTV/r + DSV ± RBV) and
TPV + PegIFN/RBV.
Methods: Treatment-naïve (MALACHITE-I) or PegIFN/RBV-
experienced (MALACHITE-II) non-cirrhotic, chronic HCV GT1-
infected patients were randomized to OBV/PTV/r + DSVJournal of Hepatology 20
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anion-transporting polypeptide.+ weight-based RBV, OBV/PTV/r + DSV (treatment-naïve,
GT1b-infected patients only), or 12 weeks of TPV + PegIFN
+ weight-based RBV and 12–36 additional weeks of PegIFN/RBV.
The primary endpoint was sustained virologic response 12 weeks
post-treatment (SVR12). Patient-reported outcome questionnaires
evaluated mental and physical health during the studies.
Results: Three hundred eleven treatment-naïve and 148
treatment-experienced patients were randomized and dosed.
Among treatment-naïve patients, SVR12 rates were 97%
(67/69) and 82% (28/34), respectively, in OBV/PTV/r + DSV
+ RBV and TPV + PegIFN/RBV-treated GT1a-infected patients;
SVR12 rates were 99% (83/84), 98% (81/83), and 78% (32/41)
in OBV/PTV/r+ DSV + RBV, OBV/PTV/r + DSV, and TPV + PegIFN/
RBV-treated GT1b-infected patients. Among treatment-
experienced patients, SVR12 rates were 99% (100/101) and
66% (31/47) with OBV/PTV/r + DSV + RBV and TPV + PegIFN/
RBV. Mental and physical health were generally better with
OBV/PTV/r + DSV ± RBV than TPV + PegIFN/RBV. Rates of discon-
tinuation due to adverse events (0–1% and 8–11%, respectively,
p <0.05) and rates of hemoglobin decline to <10 g/dl (0–4% and
34–47%, respectively, p <0.05) were lower for OBV/PTV/r
+ DSV ± RBV than TPV + PegIFN/RBV.
Conclusions: Among non-cirrhotic, HCV GT1-infected patients,
SVR12 rates were 97–99% with 12 week, multi-targeted OBV/
PTV/r + DSV ± RBV regimens and 66–82% with 24–48 total weeks
of TPV + PegIFN/RBV. OBV/PTV/r + DSV ± RBV was associated16 vol. 64 j 19–28
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with a generally better mental and physical health, more favor-
able tolerability, and lower rates of treatment discontinuation
due to adverse events.
 2015 The Authors. Published by Elsevier B.V. on behalf of the
European Association for the Study of the Liver. This is an open
access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatitis C virus (HCV) genotype (GT) 1 is the most prevalent
HCV GT worldwide [1]. In treatment-naïve GT1-infected patients,
triple therapy with the first generation HCV NS3/4A protease
inhibitor telaprevir and pegylated interferon/ribavirin (TPV
+ PegIFN/RBV) results in sustained virologic response (SVR) rates
of approximately 75% [2]. Among patients who previously failed
to achieve SVR with PegIFN/RBV therapy, retreatment with TPV
+ PegIFN/RBV results in SVR rates of 31–84% depending on type
of previous response [3]. TPV + PegIFN/RBV therapy requires up
to 48 weeks of treatment and results in significant adverse events
such as influenza-like symptoms, depression, rash, nausea, and
pancytopenia, leading to a high discontinuation rate [2,4–6].
Many patients are PegIFN-intolerant or have contraindications
to PegIFN/RBV therapy that preclude the treatment. New direct-
acting antiviral (DAA) therapies that provide a significant
advancement in chronic HCV treatment are approved and have
replaced TPV + PegIFN/RBV in many areas. However, TPV
+ PegIFN/RBV is still widely available and remains the choice
treatment in regions including Latin America and Asia. There is
a lack of direct comparison between the IFN-free DAA regimens
and previous standard of care such as TPV + PegIFN/RBV.
The 3-DAA combination regimen of ombitasvir (OBV), pari-
taprevir co-administered with ritonavir (PTV/r), and dasabuvir
(DSV) ± RBV is approved for treatment of HCV GT1-infected
patients with or without cirrhosis in areas including the United
States, Canada, and the European Union [7]. OBV is an NS5A inhi-
bitor, PTV is a HCV NS3/4A protease inhibitor, and DSV is a non-
nucleoside NS5B polymerase inhibitor [8]. In phase III trials, these
3-DAA regimens results in SVR12 rates of 95–100% in GT1a- and
GT1b-infected treatment-naïve and PegIFN/RBV-experienced,
non-cirrhotic and cirrhotic patients; discontinuation due to
adverse events occurred in 0–2% of patients [7,9–13]. Here, we
report the results obtained from the first trials performing
head-to-head comparisons on the safety and efficacy of a
PegIFN-free regimen (OBV/PTV/r + DSV ± RBV) and previous stan-
dard of care (TPV + PegIFN/RBV) in treatment-naïve
(MALACHITE-I) and treatment-experienced (MALACHITE-II) HCV
GT1-infected patients without cirrhosis.Patients and methods
Study design and participants
MALACHITE-I and MALACHITE-II (Clinicaltrials.gov, NCT01854697 and
NCT01854528) are phase IIIb, randomized, open-label studies. MALACHITE-I
enrolled patients in Australia, Canada, Europe, and South America.
MALACHITE-II enrolled patients in Australia, Europe, and South America. Patients
were 18–65 years of age with chronic HCV GT1 infection and HCV RNA
>10,000 IU/ml. Exclusion criteria included positive hepatitis B surface antigen
or anti-HIV antibody screen, and current or past evidence of cirrhosis. In20 Journal of Hepatology 20MALACHITE-I, patients with previous use of anti-HCV therapy were excluded.
Patients in MALACHITE-II had documentation of adherence with previous
PegIFN/RBV therapy with a prior relapse (undetectable HCV RNA at the end of
therapy with HCV RNA detectable within 52 weeks of treatment follow-up), par-
tial response (P2 log10 IU/ml reduction in HCV RNA at week 12 of therapy, but
HCV RNA detectable at the end of treatment), or null response (<2 log10 IU/ml
reduction in HCV RNA at week 12 of treatment or <1 log10 IU/ml reduction in
HCV RNA at week 4 of therapy). Details are in the Supplementary data.
Ethics committee approval was obtained. Each patient provided written
informed consent. The study was conducted in accordance with International
Conference on Harmonization guidelines and Declaration of Helsinki ethical
principles.
Randomization
In MALACHITE-I, HCV GT1a-infected patients were randomized 2:1 to OBV/PTV/r
+ DSV + RBV (arm A) or TPV + PegIFN/RBV (arm B). HCV GT1b-infected patients
were randomized 2:2:1 to OBV/PTV/r + DSV + RBV (arm C), OBV/PTV/r + DSV
(arm D), or TPV + PegIFN/RBV (arm E). Randomization was stratified by IL28B
genotype (CC, non-CC). In MALACHITE-II, patients were randomized 2:1 to
OBV/PTV/r + DSV + RBV or TPV + PegIFN/RBV. Randomization was stratified by
HCV subgenotype (1a, non-1a) and previous response to PegIFN/RBV treatment
(relapsers, partial responders, null responders). Random allocation sequences
were computer-generated by the sponsor and interactive response technology
was utilized for randomization of patients to treatment. Treatment allocation
was open-label.
Procedures
Patients received 12 weeks of co-formulated OBV/PTV/r (25 mg/150 mg/100 mg
once daily) and DSV (250 mg twice daily) with or without weight-based RBV or
12 weeks of TPV (750 mg every 8 h) co-administered with PegIFN (PegIFN
alpha-2a, 180 lg subcutaneously weekly) and weight-based RBV with an addi-
tional 12 or 36 weeks of PegIFN/RBV, depending on virologic response at treat-
ment week 4–12. Total daily dose of RBV was 1000 mg for body weight <75 kg
or 1200 mg for body weightP75 kg, administered in two daily doses. All patients
were followed for 48 weeks post-treatment. Adherence was assessed by pill and
syringe counts and Medication Event Monitoring System (MEMS) caps, which
record daily dosing history.
HCV RNA was measured at screening, baseline, and at visits throughout the
treatment and post-treatment periods. RNA extraction and determination of
plasma HCV RNA levels were performed by a central laboratory. The Roche High
Pure System Viral Nucleic Acid Kit was used for RNA extraction. Plasma HCV RNA
level determination was by the Roche COBAS TaqMan real-time reverse
transcriptase-PCR assay v2.0 (lower limit of detection [LLOD] and lower limit of
quantitation [LLOQ] are 15 IU/ml and 25 IU/ml, respectively). On-treatment viro-
logic failure was defined as confirmed HCV RNA PLLOQ after HCV RNA <LLOQ
during treatment, a confirmed increase in HCV RNA from nadir >1 log10 IU/ml
during treatment, or failure to achieve HCV RNA <LLOQ by week 6 (OBV/PTV/r
+ DSV ± RBV arms) or week 16 (TPV + PegIFN/RBV arms). Post-treatment relapse
was defined as confirmed HCV RNAPLLOQ after the end of treatment in a patient
who completed treatment with HCV RNA <LLOQ at final treatment visit.
Resistance-associated variant (RAV) testing was by population sequencing at
baseline and population and/or clonal sequencing at post-baseline.
Patients completed the Short Form–36 version 2 Health Survey (SF-36v2), a
self-administered patient-reported outcome (PRO) questionnaire assessing func-
tional health and well-being. Scores are aggregated into a mental component
summary (MCS) and a physical component summary (PCS), with higher scores
indicating better health. The SF-36v2 was completed at baseline and every
4–12 weeks. Patients also completed a Work Productivity and Activity Impair-
ment questionnaire specific for HCV (WPAI-HCV, details in Supplementary data).
Treatment-emergent adverse events were defined as those occurring
between treatment day 1 and 30 days post-treatment. Clinical laboratory testing
was performed at screening, baseline, and at visits throughout the treatment and
post-treatment periods.
Outcomes
In both studies, the primary endpoint was percentage of patients with SVR12
(HCV RNA <LLOQ 12 weeks after the last dose of study drug). Secondary
endpoints included mean change from baseline to final treatment visit in the
SF-36v2 MCS and PCS and percentages of patients with on-treatment virologic
failure and post-treatment relapse.16 vol. 64 j 19–28
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Fig. 1. Study designs. *PegIFN/RBV was administered without TPV for an
additional 12–36 weeks, per local prescribing information. GT, genotype; OBV,
ombitasvir; PTV, paritaprevir; DSV, dasabuvir; RBV, ribavirin; TPV, telaprevir;
pegIFN, peginterferon. Gray bars indicate post-treatment follow-up period.
Diamonds indicate time of SVR12 analysis.
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Statistical analysis
In MALACHITE-I, the primary efficacy analysis tested non-inferiority of SVR12
rates for OBV/PTV/r + DSV + RBV to TPV + PegIFN/RBV in GT1a-infected patients
(arm A vs. B) and OBV/PTV/r + DSV to TPV + PegIFN/RBV in GT1b-infected patients
(arm D vs. E). Because a previous trial demonstrated non-inferiority of OBV/PTV/r
+ DSV to OBV/PTV/r + DSV + RBV in GT1b-infected patients, arm D rather than
arm C was compared with arm E in the primary efficacy analysis in GT1b-
infected patients per protocol [11]. The percentage of patients achieving SVR12
in each arm and a 2-sided 95% confidence interval (CI) for the difference in
SVR12 rates (arm A–B, arm D–E) were calculated. If the lower bound of the CI
for the difference was above the non-inferiority margin (10.5%), OBV/PTV/r
+ DSV ± RBV was considered non-inferior to TPV + PegIFN/RBV in that subgeno-
type. In secondary endpoint analyses, mean changes in SF36-v2 MCS and PCS
scores from baseline to final treatment visit were compared in arm A vs. B and
arm D vs. E using an ANCOVA model with treatment arm as a factor and baseline
SF-36v2 MCS or PCS score, respectively, and region as covariates. SVR12 rates in
arm A vs. B and arm D vs. E were compared using a logistic regression model with
treatment arm, baseline log10 HCV RNA level, and IL28B genotype (CC, non-CC) as
predictors at the a = 0.05 significance level. If the logistic regression failed to con-
verge, a stratum-adjusted Mantel Haenszel approach was used. Mean changes
from baseline to final treatment visit in SF-36v2 MCS and PCS scores were com-
pared between regimens in all treatment-naïve patients (1a- and 1b-infected) in
post hoc analyses.
In MALACHITE-II, the primary efficacy analysis compared the percentage of
patients achieving SVR12 between treatment arms using a logistic regression
model with treatment arm, baseline log10 HCV RNA level, HCV subgenotype
(1a, non-1a), and previous PegIFN/RBV treatment response (relapser, partial
responder, null responder) as predictors at the a = 0.05 significance level. In sec-
ondary efficacy analyses, mean changes in SF-36v2 MCS and PCS scores from
baseline to final treatment visit were compared between treatment arms using
an ANCOVA model with treatment arm as a factor and baseline SF36-v2 MCS or
PCS score, respectively, and region as covariates.
Each study used a fixed-sequence testing procedure for primary and sec-
ondary efficacy analyses to control the type I error rate. In MALACHITE-I, the test-
ing procedure was conducted in GT1a- and 1b-infected patients separately; the
order of analyses within each subgenotype was: SVR12 non-inferiority, SF-36v2
MCS, SF-36v2 PCS, and SVR12 superiority. In MALACHITE-II, the order of analyses
was SVR12 analysis, SF-36v2 MCS analysis, and SF-36v2 PCS analysis. Details of
efficacy endpoint analyses and sample size determination for each study are in
the Supplementary data.
Demographic, efficacy, and safety analyses were on the modified intention-
to-treat population, defined as all patients who were randomized and received
P1 dose of study drug. SAS (SAS Institute, Inc., Cary, NC) for the UNIX operating
system was used for all analyses. All statistical tests and CIs were 2-sided with an
a level of 0.05. CIs were calculated using normal approximation to the binomial
distribution unless the point estimate was 0% or 100%, in which case Wilson score
method was used. Frequencies of treatment-emergent adverse events and post-
baseline laboratory abnormalities were compared between treatment groups by
Fisher’s exact test.Results
In the treatment-naïve study, 404 patients were screened; 311
were randomized and received study drug (Fig. 1, Supplementary
Fig. 1). In the treatment-experienced study, 222 patients were
screened, 154 were randomized, and 148 received study drug
(Fig. 1; Supplementary Fig. 2). Reasons for exclusion are in
Supplementary Tables 1 and 2. Patient characteristics are in
Table 1. In each study the majority of patients (P95% receiving
OBV/PTV/r + DSV ± RBV and P86% receiving TPV + PegIFN/RBV)
were adherent with planned dosing of each study drug. Among
75 treatment-naïve patients receiving TPV + PegIFN/RBV, 59
received 24 weeks of PegIFN/RBV while 16 received 48 weeks.
Among 47 treatment-experienced patients receiving TPV
+ PegIFN/RBV, 10 received a 24-week regimen (all prior relapsers)
and 37 received a 48-week regimen (2 relapsers, 12 partial
responders, 23 null responders).Journal of Hepatology 20Efficacy
Treatment-naïve patients (MALACHITE-I)
Among HCV GT1a-infected patients, 97% (67/69) (95% CI 93–100)
receiving OBV/PTV/r + DSV + RBV and 82% (28/34) (95% CI 69–96)
receiving TPV + PegIFN/RBV achieved SVR12 (Fig. 2). The SVR12
rate difference of 15% (95% CI 1–28) demonstrated protocol-
defined non-inferiority of OBV/PTV/r + DSV + RBV to TPV
+ PegIFN/RBV in GT1a-infected patients. Among HCV GT1b-
infected patients, 98% (81/83) (95% CI 94–100) receiving OBV/
PTV/r + DSV and 78% (32/41) (95% CI 66–91) receiving TPV
+ PegIFN/RBV achieved SVR12. The difference of 20% (95% CI
6–33) demonstrated protocol-defined non-inferiority of OBV/
PTV/r + DSV to TPV + PegIFN/RBV in GT1b-infected patients. The
SVR12 rate for OBV/PTV/r + DSV was also superior to TPV
+ PegIFN/RBV (p = 0.005). The SVR12 rate of 99% (83/84) (95% CI
97–100) in OBV/PTV/r + DSV + RBV-treated, GT1b-infected
patients was non-inferior (difference = 21%, 95% CI 8–34%) and
superior (p = 0.002) to that for TPV + PegIFN/RBV.
Four of 236 patients (2%) receiving OBV/PTV/r + DSV ± RBV vs.
9 of 75 patients (12%) receiving TPV + PegIFN/RBV met protocol-
specified criteria for on-treatment virologic failure or post-
treatment relapse (Table 2). Available data showed the three
patients receiving OBV/PTV/r + DSV ± RBV with on-treatment
virologic failure were adherent to study drugs. At the time of fail-
ure, these patients had variants at resistance-associated positions
in the amino acid sequences for NS3, NS5A, and/or NS5B that
were not present at baseline. One GT1b-infected patient receiving
OBV/PTV/r + DSV + RBV met the criteria for post-treatment
relapse but had GT2a infection, consistent with reinfection. Most
patients in the TPV + PegIFN/RBV arm who experienced virologic
failure had RAVs present in NS3 at the time of failure.16 vol. 64 j 19–28 21
Table 1. Demographic and baseline characteristics.
Treatment-naive  
(MALACHITE-I)
Treatment-experienced  
(MALACHITE-II)
Arm A
OBV/PTV/r + 
DSV + RBV
GT1a
N = 69
Arm B
TPV
+ PegIFN/RBV
GT1a
N = 34
Arm C
OBV/PTV/r + 
DSV + RBV
GT1b
N = 84
Arm D
OBV/PTV/r + 
DSV
GT1b
N = 83
Arm E
TPV
+ PegIFN/RBV
GT1b
N = 41
OBV/PTV/r 
+ DSV + RBV
N = 101
TPV +
PegIFN/RBV
N = 47
Male sex 48 (70%) 17 (50%) 38 (45%) 40 (48%) 17 (41%) 55 (54%) 28 (60%)
White race 62 (90%) 30 (88%) 80 (95%) 82 (99%) 38 (93%) 101 (100%) 47 (100%)
Hispanic or Latino 
ethnicity
12 (17%) 3 (9%) 12 (14%) 15 (18%) 3 (7%) 12 (12%) 2 (4%)
Age, years 46.1 (12.3) 44.5 (14.1) 46.2 (11.3) 47.1 (11.3) 45.9 (10.8) 46.9 (12.2) 45.0 (10.4)
Body mass index, kg/m2 26.6 (4.9) 25.8 (3.6) 25.5 (3.6) 25.4 (4.0) 25.2 (3.6) 25.9 (4.0) 26.4 (4.1)
HCV genotype
1a 69 (100%) 34 (100%) 0 0 0 19 (19%) 7 (15%)
1b 0 0 84 (100%) 83 (100%) 41 (100%) 82 (81%) 40 (85%)
IL28B genotype, non-CC 50 (72%) 23 (68%) 70 (83%) 69 (83%) 34 (83%) 93 (92%) 41 (87%)
Fibrosis stage
F0-F1 49 (72%) 24 (71%) 70 (83%) 60 (72%) 31 (76%) 79 (78%) 32 (68%)
F2 12 (18%) 7 (21%) 7 (8%) 11 (13%) 4 (10%) 17 (17%) 11 (23%)
≥F3 7 (10%) 3 (9%) 7 (8%) 12 (14%) 6 (15%) 5 (5%) 4 (9%)
HCV RNA, log10 IU/ml 6.29 (0.8) 6.37 (0.8) 6.36 (0.6) 6.33 (0.6) 6.23 (0.7) 6.37 (0.50) 6.39 (0.50)
Type of response to previous pegIFN/RBV treatment
Relapse n.a. n.a. n.a. n.a. n.a. 27 (27%) 12 (26%)
Partial response 25 (25%) 12 (26%)
Null response 49 (49%) 23 (49%)
Data are mean (SD) or n (%). OBV, ombitasvir; PTV, paritaprevir; DSV, dasabuvir; RBV, ribavirin; TPV, telaprevir; PegIFN, pegylated interferon; n.a, not applicable. Fibrosis
stage was assessed by liver biopsy scores, FibroScan scores, or FibroTest scores (Supplementary Table 3). Fibrosis stage was missing for one treatment-naïve HCV GT1a-
infected patient receiving OBV/PTV/r + DSV + RBV.
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Fig. 2. SVR12 rates. Bars indicate 95% confidence intervals. p value shown for arm
C vs. E is based on logistic regression. p value shown for arm D vs. E is based on a
stratum-adjusted Mantel Haenszel approach. SVR12 rate was not compared
between arms A and B by logistic regression analysis as the fixed-sequence
testing procedure concluded with the failure of the SF-36v2 MCS analysis in
GT1a-infected patients. In treatment-experienced patients p value is based on a
logistic regression. OBV, ombitasvir; PTV, paritaprevir; DSV, dasabuvir; RBV,
ribavirin; TPV, telaprevir; PegIFN, peginterferon, GT, genotype.
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A total of 100 of 101 patients receiving OBV/PTV/r + DSV + RBV
achieved SVR12 (99%, 95% CI 97–100%) (Fig. 2). Thirty-one of 47
patients receiving TPV + PegIFN/RBV achieved SVR12 (66%, 95%22 Journal of Hepatology 20CI 53–79%). SVR12 rate was significantly different between treat-
ment arms (odds ratio = 54, 95% CI 7–430; p <0.001). SVR12 rates
were numerically higher with OBV/PTV/r + DSV + RBV than TPV
+ PegIFN/RBV in subgroups of patients based on genotype or prior
treatment experience (Supplementary Table 4). SVR12 rates were
100% (49/49) and 57% (13/23) in prior null responders receiving
OBV/PTV/r + DSV + RBV and TPV + PegIFN/RBV, respectively.
There were no on-treatment failures or post-treatment
relapses with OBV/PTV/r + DSV + RBV; the one patient not achiev-
ing SVR12 had missing data, but had HCV RNA <LLOQ at the end of
treatment (Table 2). Among patients receiving TPV + PegIFN/RBV,
23% met protocol-specified criteria for virologic failure. Most
patients receiving TPV + PegIFN/RBV who experienced virologic
failure had RAVs present in NS3 at the time of failure.
Patient-reported outcomes
Mean changes from baseline to final treatment and post-
treatment week 12 visit in SF-36v2 MCS and PCS in treatment-
naïve and treatment-experienced patients are in Fig. 3. When
GT1a- and GT1b-infected treatment-naïve patients were ana-
lyzed separately, mean changes at the final treatment visit in
MCS and PCS with OBV/PTV/r + DSV ± RBV vs. TPV + PegIFN/RBV
were significantly different in GT1b-infected patients (p <0.05).
Mean change in MCS was not significantly different for OBV/
PTV/r + DSV + RBV vs. TPV + PegIFN/RBV in GT1a-infected
patients, preventing statistical testing of subsequent secondary
endpoints in GT1a-infected patients per protocol. In a post hoc
analysis, mean changes at the final treatment visit in SF-36v2
MCS and PCS were significantly different between patients16 vol. 64 j 19–28
Table 2. Reasons for non-response.
Treatment-naive 
(MALACHITE-I)
Treatment-experienced
(MALACHITE-II)
Arm A
OBV/PTV/r + 
DSV + RBV
GT1a
N = 69
Arm B
TPV
+ PegIFN/RBV
GT1a
N = 34
Arm C
OBV/PTV/r + 
DSV + RBV
GT1b
N = 84
Arm D
OBV/PTV/r + 
DSV
GT1b
N =  83
Arm E
TPV
+ PegIFN/RBV
GT1b
N = 41
OBV/PTV/r + 
DSV + RBV
N = 101
TPV
+ PegIFN/RBV
N = 47
On-treatment failure 2/69,
3%
(0-7)
2/34,
6%
(0-14)
0
(0-4)
1/83,
1%
(0-4)
5/41,
12%
(2-22)
0 
(0-4)
9/47, 
19% 
(8-30)
Post-treatment relapse 0
(0-6)
0
(0-12)
1/84,*
1%
(0-4)
0
(0-5)
2/32,
6%
(0-15)
0 
(0-4)
2/32, 
6% 
(0-15)
Failure to achieve 
SVR12 due to other 
reasons†
0 4/34, 
12%
0 1/83, 
1%
2/41, 
5% 
1/101, 
1%
5/47, 
11%
Data are n/N,% (95% CI) or n/N,%. OBV, ombitasvir; PTV, paritaprevir; DSV, dasabuvir; RBV, ribavirin; TPV, telaprevir; PegIFN, peginterferon, GT, genotype.
*This patient had GT2a infection upon recurrence of viremia, consistent with reinfection.
yOther reasons were missing SVR12 data or premature study drug discontinuation.
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Fig. 3. Mean changes in SF-36v2 mental and physical component summary scores from baseline to end of treatment and to post-treatment week 12. Bars show
mean scores at baseline (determined for patients with end of treatment data), end of treatment, and post-treatment week 12. Numbers over bars are mean changes
(standard deviation). Mean changes and standard deviations for post-treatment week 12 are based on the baseline for patients who had post-treatment week 12 data. Thus,
in some cases, this baseline differs from the baseline presented (for patients with end of treatment data), but does not impact the interpretation. Analyses in all treatment-
naïve patients were not pre-specified. Mean change in PCS was not compared between arms A and B by logistic regression analysis as the fixed-sequence testing procedure
concluded with the failure of the SF-36v2 MCS analysis in GT1a-infected patients. *, **, *** indicates p <0.05, p <0.01 and p <0.001, respectively, for comparison to TPV
+ pegIFN/RBV arm. OBV, ombitasvir; PTV, paritaprevir; DSV, dasabuvir; RBV, ribavirin; TPV, telaprevir; pegIFN, peginterferon; BL, baseline; EOT, end of treatment (final
treatment visit); PTW12, post-treatment week 12.
JOURNAL OF HEPATOLOGYreceiving OBV/PTV/r + DSV ± RBV and TPV + PegIFN/RBV in the
overall population of treatment-naïve patients (p <0.05).
Similarly, mean changes in SF-36v2 MCS and PCS were signifi-
cantly different between patients receiving OBV/PTV/r
+ DSV ± RBV and TPV + PegIFN/RBV in the overall population of
treatment-experienced patients (p <0.05). Overall, mean changes
at post-treatment week 12 in MCS and PCS were not significantly
different between OBV/PTV/r + DSV ± RBV and TPV + PegIFN/RBV
in treatment-naïve or -experienced patients. Across the two stud-
ies, 46% and 58% of patients receiving OBV/PTV/r + DSV ± RBVJournal of Hepatology 20showed numerical improvement over baseline at final treatment
visit in MCS and PCS, respectively; 27% and 22% of patients
receiving TPV + PegIFN/RBV showed numerical improvement in
MCS and PCS, respectively. Overall, the difference between the
two regimens in the changes from baseline in MCS and PCS
throughout the treatment and post-treatment periods in both
treatment-naïve and treatment-experienced patients favored
the OBV/PTV/r + DSV ± RBV regimen (Fig. 4). Comparable
differences in WPAI-HCV between regimens were observed
(Supplementary Fig. 3).16 vol. 64 j 19–28 23
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Fig. 4. Mean changes from baseline during the treatment and post-treatment periods in SF-36v2 mental and physical component summary scores. OBV, ombitasvir;
PTV, paritaprevir; DSV, dasabuvir; RBV, ribavirin; TPV, telaprevir; pegIFN, peginterferon; BL, baseline; W, treatment week; PTW, post-treatment week.
Research ArticleAdverse events
Safety data were combined according to treatment regimen
within each study. Adverse event frequency was lower with
OBV/PTV/r + DSV ± RBV vs. TPV + PegIFN/RBV (p <0.05) (Table 3).
The majority of treatment-emergent adverse events observed
were mild with OBV/PTV/r + DSV ± RBV and moderate with TPV
+ PegIFN/RBV. Notably, rash occurred less frequently with OBV/
PTV/r + DSV ± RBV vs. TPV + PegIFN/RBV (p <0.05). One
treatment-naïve patient receiving TPV + PegIFN/RBV but none
receiving OBV/PTV/r + DSV ± RBV experienced toxic skin erup-
tion. The rates of adverse events commonly associated with
RBV, such as anemia, pruritus, rash, nausea, and asthenia, were
lower with OBV/PTV/r + DSV + RBV vs. TPV + PegIFN/RBV
(p <0.05). Depression was also less frequent with OBV/PTV/r
+ DSV ± RBV than TPV + PegIFN/RBV (0–2% vs. 6–9%, p <0.05). In
treatment-naïve GT1b-infected patients, the frequencies of these
adverse events were numerically lower with OBV/PTV/r + DSV
than OBV/PTV/r + DSV + RBV, consistent with their known associ-
ation with RBV.
In both studies the rates of serious adverse events and treat-
ment discontinuation due to adverse events were lower with
OBV/PTV/r + DSV ± RBV vs. TPV + PegIFN/RBV (p <0.05). Serious
adverse events occurred in two patients receiving OBV/PTV/r
+ DSV + RBV (one treatment-naïve [1%] and one treatment-
experienced [1%]), no patient receiving OBV/PTV/r + DSV, and
14 patients receiving TPV + PegIFN/RBV (9 treatment-naïve
[12%], 5 treatment-experienced [11%]). One treatment-naïve
patient (1%) receiving OBV/PTV/r + DSV + RBV and no patient
receiving OBV/PTV/r + DSV discontinued treatment due to
adverse events, vs. 6 treatment-naïve patients (8%) and five
treatment-experienced patients (11%) receiving TPV + PegIFN/
RBV. Details are in Supplementary Tables 5 and 6.
Decreased hemoglobin levels
Among treatment-naïve patients, three receiving OBV/PTV/r
+ DSV + RBV (2%), none receiving OBV/PTV/r + DSV, and 35
receiving TPV + PegIFN/RBV (47%) had hemoglobin decline to24 Journal of Hepatology 20<10 g/dl (p <0.05, vs. TPV + PegIFN/RBV) (Table 3). Among
treatment-experienced patients, four receiving OBV/PTV/r+ DSV
+ RBV (4%) vs. 16 receiving TPV + PegIFN/RBV (34%) had hemoglo-
bin declines to <10 g/dl (p <0.05). Five treatment-naïve patients
(3%) and two treatment-experienced patients (2%) receiving
OBV/PTV/r + DSV + RBV modified RBV dose due to anemia; all
achieved SVR12. Thirty-two treatment-naïve patients (43%) and
15 treatment-experienced patients (32%) receiving TPV
+ PegIFN/RBV modified RBV dose due to anemia; SVR12 rates
were 84% and 93% in treatment-naïve and treatment-
experienced patients, respectively. Twelve patients receiving
TPV + PegIFN/RBV (6 treatment-naïve, 6 treatment-experienced)
had a blood transfusion, and one treatment-experienced patient
received erythropoietin.
Other laboratory abnormalities
No patient discontinued OBV/PTV/r + DSV ± RBV due to labora-
tory abnormalities. Six treatment-naïve patients (4%) and one
treatment-experienced patient (1%) receiving OBV/PTV/r + DSV
+ RBV had total bilirubin elevations >3 the upper limit of nor-
mal (ULN) (Table 3). These elevations were comprised mainly
of indirect bilirubin, peaked at week 1 of treatment, and normal-
ized or stabilized thereafter. Total bilirubin elevations >3 ULN
occurred in two treatment-naïve patients (3%) and one
treatment-experienced patient (2%) receiving TPV + PegIFN/RBV.
One treatment-naïve patient (1%) receiving OBV/PTV/r + DSV
+ RBV had isolated elevations of aminotransferases >5 ULN
within the first month of treatment that led to study drug inter-
ruption for 14 days. Aminotransferase levels normalized by post-
treatment week 4. The patient had no other liver function test
abnormalities, and achieved SVR12. One (1.0%) treatment-
experienced patient receiving OBV/PTV/r + DSV + RBV and three
(6.4%) receiving TPV + PegIFN/RBV had at least one alanine
aminotransferase measurement >5 ULN. In the patient receiving
OBV/PTV/r + DSV + RBV this elevation was concurrent with an
elevation in aspartate aminotransferase >5 ULN. These values
declined without treatment interruption or discontinuation and16 vol. 64 j 19–28
Table 3. Numbers of patients with treatment-emergent adverse events.
Treatment-naive
 (MALACHITE-I)
Treatment-experienced
 (MALACHITE-II)
Arm A + C
OBV/PTV/r + DSV
+ RBV
N = 153
Arm D
OBV/PTV/r + DSV
N = 83
Arm B + E
TPV
+ PegIFN/RBV
N = 75
OBV/PTV/r + DSV
+ RBV
N = 101
TPV
+ PegIFN/RBV
N = 47
Any adverse event 115 (75%)* 41 (49%)* 74 (99%) 63 (62%)* 43 (91%)
Severe adverse event 5 (3%)* 0* 14 (19%) 1 (1%) 2 (4%)
Moderate or severe adverse 
event
47 (31%)* 13 (16%)* 61 (81%) 18 (18%)* 34 (72%)
Serious adverse event 1 (1%)* 0* 9 (12%) 1 (1%)* 5 (11%)
Adverse event leading to 
discontinuation of study 
treatment
1 (1%)* 0* 6 (8%) 0* 5 (11%)
Adverse events occurring in ≥20% of patients in any group
Headache 41 (27%) 16 (19%) 23 (31%) 29 (29%) 21 (45%)
Nausea 32 (21%)* 7 (8%)* 30 (40%) 10 (10%)* 20 (43%)
Pruritus 19 (12%)* 5 (6%)* 26 (35%) 13 (13%)* 19 (40%)
Fatigue 21 (14%)* 4 (5%)* 23 (31%) 12 (12%) 12 (26%)
Anemia 10 (7%)* 1 (1%)* 34 (45%) 3 (3%)* 16 (34%)
Rash 12 (8%)* 0* 17 (23%) 3 (3%)* 12 (26%)
Asthenia 11 (7%)* 2 (2%)* 15 (20%) 8 (8%)* 16 (34%)
Decreased appetite 6 (4%)* 1 (1%)* 17 (23%) 3 (3%)* 8 (17%)
Pyrexia 4 (3%)* 2 (2%)* 16 (21%) 2 (2%)* 15 (32%)
Anal pruritus 1 (1%)* 0* 10 (13%) 0* 12 (26%)
Neutropenia 0* 0* 14 (19%) 1 (1%)* 12 (26%)
Cough 11 (7%) 1 (1%)* 9 (12%) 7 (7%)* 12 (26%)
Insomnia 14 (9%) 0* 7 (9%) 6 (6%)* 10 (21%)
Post-baseline abnormalities in laboratory values 
Hemoglobin
8-<10 g/dl 2/153 (1%) 0/83 32/74 (43%) 4/101 (4%) 12/47 (26%)
<8 g/dl     1/153 (1%) 0/83 3/74 (4%) 0/101 4/47 (9%)
Alanine aminotransferase 
>5x ULN
1/153 (1%) 0/83 0/74 1/101 (1%) 3/47 (6%)
Aspartate aminotransferase 
>5x ULN
1/153 (1%) 1/83 (1%) 0/74 1/101 (1%) 1/47 (2%)
Total bilirubin >3x ULN 6/153 (4%) 0/83 2/74 (3%) 1/101 (1%) 1/47 (2%)
Data are n (%). ULN, upper limit of normal; OBV, ombitasvir; PTV, paritaprevir; DSV, dasabuvir; RBV, ribavirin; TPV, telaprevir; PegIFN, peginterferon. In treatment-naïve
patients, the OBV/PTV/r + DSV + RBV group includes patients from arms A and C, the OBV/PTV/r + DSV group includes patients from arm D, and the TPV + PegIFN/RBV
group includes patients from arms B and E. Adverse events occurring in P10% of patients in any group and additional data on laboratory values are in Supplementary
Tables 7 and 8.
* Statistically significant difference vs. the TPV + PegIFN/RBV group of the same prior treatment status (p <0.05).
JOURNAL OF HEPATOLOGYnormalized at post-treatment week 4; this patient had no clini-
cally significant bilirubin elevation.Discussion
Significant advances have occurred rapidly in chronic HCV
treatment with approval of new DAAs. Studies of DAA regimens
in HCV GT1-infected patients have demonstrated higher SVR
rates and better tolerability profiles than previously reported
for first generation protease inhibitors co-administered with
PegIFN/RBV [2,9–18]. However, evidence-based policy centers
have highlighted the lack of direct comparative trials demon-
strating the efficacy and safety benefits of IFN-free regimens
vs. PegIFN-containing regimens [19]. This is the first report of
head-to-head studies of an all-oral, DAA (OBV/PTV/r
+ DSV ± RBV) and a PegIFN-containing (TPV + PegIFN/RBV) regi-
men that quantitatively compares efficacy and safety benefitsJournal of Hepatology 20in treatment-naïve and treatment-experienced HCV GT1-
infected patients.
As expected based upon results of previous trials, the SVR12
rate was numerically higher with OBV/PTV/r + DSV ± RBV than
TPV + PegIFN/RBV regardless of subgenotype or prior treatment
status [2,9–13,17]. The efficacy difference between the regimens
persisted despite numerically higher SVR rates for TPV + PegIFN/
RBV than previously reported [2,13]. The higher SVR rates of TPV
+ PegIFN/RBV may be related to exclusion of cirrhotic patients
and absence of black patients, who are less likely to respond to
TPV + PegIFN/RBV, and improved management of adverse events
associated with TPV-containing regimens by experienced health-
care providers [2,17,20,21].
PRO assessments provide patients’ perspective on the impact
of treatment on daily life and work. PROs were evaluated using
the SF-36v2 and WPAI-HCV instruments, which are standard
PRO tools for general diseased and HCV-infected populations,
respectively. In general, mean changes in SF-36v2 MCS and PCS16 vol. 64 j 19–28 25
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scores from baseline were numerically or significantly different
between OBV/PTV/r + DSV ± RBV and TPV + PegIFN/RBV through-
out the treatment period, with the difference indicating better
mental and physical health in patients receiving OBV/PTV/r
+ DSV ± RBV. Decreases in health-related quality of life through
treatment week 12 and return to baseline after treatment have
previously been reported for patients receiving TPV + PegIFN/
RBV [22]. The largest differences in mental and physical health
between the two regimens were observed at treatment week
12. SF-36v2 MCS in patients on all regimens and PCS scores in
patients on TPV + PegIFN/RBV were near baseline levels by
post-treatment week 12; improvement in PCS scores over base-
line was observed as early as treatment week 8 in patients on
OBV/PTV/r + DSV ± RBV. Similarly, mean changes in WPAI-HCV
scores indicate that patients receiving OBV/PTV/r + DSV ± RBV
were better able to perform work during treatment than patients
receiving TPV + PegIFN/RBV. These findings indicating improved
health-related quality of life in patients receiving an IFN-free vs.
an IFN-containing regimen are consistent with previous reports
examining regimens separately [2,23–26].
While PROs were evaluated using standard PRO tools for this
population, these analyses had limitations. The impact of knowl-
edge of treatment efficacy on PROmeasures is not known, as there
were no specific instructions to investigators on informing
patients of their virologic response before PRO questionnaire com-
pletion. Furthermore, the studies were not specifically designed to
assess the potential impact of physiological differences (e.g. ane-
mia associated with IFN or RBV use) on changes in PRO measures.
Safety data support better tolerability of OBV/PTV/r
+ DSV ± RBV than TPV + PegIFN/RBV regardless of subgenotype
or prior treatment status. Across groups of patients receiving
OBV/PTV/r + DSV ± RBV there were up to four adverse events
with a frequency of >10% while across groups of patients receiv-
ing TPV + PegIFN/RBV there were up to 24 adverse events with a
frequency of >10%, demonstrating the contrast in breadth of
symptoms experienced by patients on the regimens. While the
frequency of common adverse events was numerically higher
with OBV/PTV/r + DSV + RBV than the RBV-free regimen in
treatment-naïve GT1b-infected patients, OBV/PTV/r + DSV + RBV
was well-tolerated and discontinuation due to adverse events
was infrequent, consistent with previous reports [11].
The adverse event profile of RBV is being redefined in the era of
PegIFN-free therapies. The numerically higher frequencies of
adverse events such as anemia, nausea, pruritus, rash, insomnia,
and asthenia in treatment-naïve patients receiving OBV/PTV/r
+ DSV + RBV vs. the RBV-free regimen suggest that these are more
likely associated with RBV use. Rates and severity of these adverse
events were significantly lower with OBV/PTV/r + DSV + RBV vs.
TPV + PegIFN/RBV. Hemoglobin declines were less frequent and
severe with OBV/PTV/r + DSV + RBV than TPV + PegIFN/RBV. The
greater frequency and severity of anemia with the PegIFN-
containing regimen may reflect bone marrow suppressant effects
of IFN that prevent compensatory reticulocytosis [27,28].
Hemoglobin declines in patients receiving OBV/PTV/r + DSV
+ RBV were managed by RBV dose modification alone while some
patients receiving TPV + PegIFN required blood transfusion or ery-
thropoietin. The high SVR12 rates among patients who reduced
RBV are consistent with previous reports indicating RBV reduction
does not impact efficacy of either regimen [9–11,13,29].
The most common laboratory abnormality with OBV/PTV/r
+ DSV ± RBV was a transient elevation in bilirubin (predomi-26 Journal of Hepatology 20nantly indirect bilirubin), consistent with the known roles of
PTV as an inhibitor of the OATP1B1 and OATP1B3 transporters
and RBV-induced hemolysis [18,30]. Alanine aminotransferase
and bilirubin elevations observed with OBV/PTV/r + DSV ± RBV
were infrequent and generally isolated abnormalities that recov-
ered without drug discontinuation, consistent with previous
studies [10–12].
The trials were designed as open-label because the well-
known adverse event profile of TPV + PegIFN/RBV prevented
effective blinding of investigators and patients. While the open-
label design may have influenced reporting of adverse events, it
would not affect objective endpoints such as SVR12 and labora-
tory abnormalities. Adverse event profiles were consistent with
those reported in blinded trials [2,10,11,13,17]. Because patients
in the United States had significant access to all-oral DAA thera-
pies through clinical trials at the time of enrollment, the United
States sites were not included. The trials were limited by the
exclusion of cirrhotic patients. The safety and efficacy of
OBV/PTV/r + DSV + RBV was previously characterized in a phase
III trial dedicated to patients with compensated cirrhosis
(N = 380); 12–24 weeks of treatment achieved SVR rates of
92–97% [12]. In cirrhotic patients, TPV + PegIFN/RBV therapy gen-
erally has a total duration of 48 weeks with reduced efficacy
compared to non-cirrhotic patients [2,3,17]. Therefore, exclusion
of cirrhotic patients should not change the general conclusions.
The treatment-experienced study was limited by the low
number of GT1a-infected patients enrolled. This resulted from
the dominance of GT1b infection in Europe, one of the major
study locations. However, 96% (166/173) of GT1a-infected
patients receiving 12 weeks of OBV/PTV/r + DSV + RBV achieved
SVR12 in a phase III trial in non-cirrhotic, treatment-
experienced patients in Australia, North America, and Europe
[13]. Because phase II data were available for treatment-naïve
but not treatment-experienced GT1b-infected patients receiving
OBV/PTV/r + DSV without RBV at the time of study design, the
treatment-experienced study did not include an arm with
GT1b-infected patients receiving the RBV-free regimen [31].
More recently available phase III data demonstrated SVR12 rates
of 100% (91/91) in treatment-experienced, GT1b-infected
patients receiving a RBV-free OBV/PTV/r + DSV regimen [9].
In HCV GT1-infected patients without cirrhosis, all-oral
12-week combination regimens of OBV/PTV/r + DSV ± RBV
demonstrate SVR12 rates of 97–99%, while 12 weeks of TPV with
24–48 weeks of PegIFN/RBV achieves SVR12 rates of 66–82%.
OBV/PTV/r + DSV ± RBV is associated with generally better men-
tal and physical health and tolerability, with lower rates of severe
and serious adverse events and treatment discontinuation due to
toxicity, compared to TPV + PegIFN/RBV. OBV/PTV/r + DSV ± RBV
represents a significant advancement over PegIFN-based regi-
mens with first generation protease inhibitors. Taken together,
data from the MALACHITE-I and -II studies support the preferen-
tial use of IFN-free regimens, where available, for the treatment
of HCV infection in this patient population.Financial support
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